Galectin Therapeutics Financials
| GALT Stock | USD 1.47 0.01 0.68% |
Galectin |
Understanding current and past Galectin Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Galectin Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Galectin Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Galectin Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Galectin Therapeutics. Check Galectin Therapeutics' Beneish M Score to see the likelihood of Galectin Therapeutics' management manipulating its earnings.
Galectin Therapeutics Stock Summary
Galectin Therapeutics competes with Madrigal Pharmaceuticals, Viking Therapeutics, Sarepta Therapeutics, Hepion Pharmaceuticals, and PTC Therapeutics. Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Galectin Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US3632252025 |
| CUSIP | 363225202 363225301 74267T109 363225103 |
| Location | Georgia; U.S.A |
| Business Address | 4960 Peachtree Industrial |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | galectintherapeutics.com |
| Phone | 678 620 3186 |
| Currency | USD - US Dollar |
Galectin Therapeutics Key Financial Ratios
| Return On Equity | -37.28 | ||||
| Return On Asset | -0.97 | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.82 |
Galectin Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Galectin Therapeutics's current stock value. Our valuation model uses many indicators to compare Galectin Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galectin Therapeutics competition to find correlations between indicators driving Galectin Therapeutics's intrinsic value. More Info.Galectin Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Galectin Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Galectin Therapeutics Systematic Risk
Galectin Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Galectin Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Galectin Therapeutics correlated with the market. If Beta is less than 0 Galectin Therapeutics generally moves in the opposite direction as compared to the market. If Galectin Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Galectin Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Galectin Therapeutics is generally in the same direction as the market. If Beta > 1 Galectin Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Galectin Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Galectin has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Galectin Therapeutics' financials are consistent with your investment objective using the following steps:- Review Galectin Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Galectin Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Galectin Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Galectin Therapeutics' stock is overvalued or undervalued.
Galectin Therapeutics Thematic Clasifications
Galectin Therapeutics is part of Israel Wall Street investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Large Israel companies traded on major USA exchanges. Cross-sector collection of best publicly traded Israel entities that are expected to continue growing
This theme covers Large Israel companies traded on major USA exchanges. Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. Get More Thematic Ideas
| Israel Wall Street | View |
Galectin Therapeutics February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Galectin Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Galectin Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Galectin Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Galectin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Galectin Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 57.48 | |||
| Value At Risk | (10.59) | |||
| Potential Upside | 11.3 |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.